Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors

Lysette N. Broekhuizen, Diederik F. van Wijk, Hans Vink, A. Stalmach, A. Crozier, Barbara A. Hutten, John J. P. Kastelein, Paul G. Hugenholtz, Wolfgang Koenig, Erik S. G. Stroes*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Web of Science)

Abstract

Inflammation is a hallmark of the metabolic syndrome, which also contributes to a pro-atherogenic state. NF-kappa B activation, a critical step in regulating inflammatory reactions, can be inhibited by polyphenol (PF) extracts, at least in vitro. In the present study, we set out to study whether a PF-rich extract could attenuate the chronic inflammatory state and/or an acute immune response in vivo in subjects with clustered metabolic risk factors. A commercially available, PF-rich extract (500mg daily) or placebo was administered for 4 weeks to thirty-four subjects with two or more metabolic risk factors using a randomised, double-blind, cross-over design. During the final study visit, an acute inflammatory challenge (lipopolysaccharide (LPS) 1 ng/kg body weight) was administered to a random subgroup of subjects (PF-rich extract (n 12) and placebo (n 12)). The PF-rich extract modestly reduced the inflammatory chemokines monocyte chemoattractant protein 1 (MCP-1) and macrophage migration inhibitory factor (MIF) (MCP-1 26.5% (PF, median 116 (interquartile range 97-136) pg/ml v. placebo, median 124 (interquartile range 105-153) pg/ml; P
Original languageEnglish
Pages (from-to)1416-1422
JournalBritish Journal of Nutrition
Volume106
Issue number9
DOIs
Publication statusPublished - Nov 2011

Keywords

  • Flow-mediated dilation
  • Polyphenols
  • Inflammation
  • Cardiometabolic risk factors
  • Monocyte chemoattractant protein 1

Cite this